Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease?
暂无分享,去创建一个
[1] Y. Matsuda,et al. Endogenous Natriuretic Peptides Participate in Renal and Humoral Actions of Acute Vasopeptidase Inhibition in Experimental Mild Heart Failure , 2001, Hypertension.
[2] T. Lüscher,et al. Vasopeptidase Inhibition Exhibits Endothelial Protection in Salt-Induced Hypertension , 2001, Hypertension.
[3] T. Lüscher,et al. Vasopeptidase Inhibition Prevents Endothelial Dysfunction of Resistance Arteries in Salt-Sensitive Hypertension in Comparison With Single ACE Inhibition , 2001, Hypertension.
[4] J. Rouleau,et al. The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins , 2000, Peptides.
[5] J. Rouleau,et al. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts. , 2000, The Journal of pharmacology and experimental therapeutics.
[6] F. Messerli,et al. Vasopeptidase inhibition and angio-oedema , 2000, The Lancet.
[7] M. Pfeffer,et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial , 2000, The Lancet.
[8] A. H. Garlick,et al. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. , 2000, Journal of the American College of Cardiology.
[9] T. LeJemtel,et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. , 2000, The New England journal of medicine.
[10] R. Asmar,et al. OMAPATRILAT COMPARED WITH LISINOPRIL IN TREATMENT OF HYPERTENSION AS ASSESSED BY AMBULATORY BLOOD PRESSURE MONITORING: P2.25 , 2000 .
[11] E. Schiffrin,et al. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. , 2000, Hypertension.
[12] R. Asmar,et al. A085: Omapatrilat compared with lisinopril in treatment of hypertension as assessed by ambulatory blood pressure monitoring , 2000 .
[13] L. Ruilope,et al. A063: Randomized double-blind comparison of omapatrilat with amlodipine in mild-to-moderate hypertension , 2000 .
[14] Kelly K Warner,et al. Angiotensin II Receptor Blockers in Patients with ACE Inhibitor–Induced Angioedema , 2000, The Annals of pharmacotherapy.
[15] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[16] J. Floras,et al. Sympathetic responses to atrial natriuretic peptide in patients with congestive heart failure. , 2000, Journal of cardiovascular pharmacology.
[17] G. Lip,et al. Angioedema due to ACE inhibitors: increased risk in patients of African origin. , 2001, British journal of clinical pharmacology.
[18] N. Trippodo,et al. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. , 1999, Journal of cardiovascular pharmacology.
[19] M. Cicardi,et al. Angioedema due to angiotensin-converting enzyme inhibitors. , 1999, Immunopharmacology.
[20] J. Rouleau,et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. , 1999, Immunopharmacology.
[21] M. J. Allen,et al. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. , 1999, American journal of hypertension.
[22] S. Yusuf,et al. Summary of randomized trials of angiotensin converting enzyme inhibitors. , 1999, Clinical and experimental hypertension.
[23] H. Drexler,et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. , 1998, Circulation.
[24] L. Ramsay,et al. Combined inhibition of neutral endopeptidase and angiotensin‐converting enzyme by sampatrilat in essential hypertension , 1998, Clinical pharmacology and therapeutics.
[25] C. Johnston,et al. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. , 1998, Hypertension.
[26] J. Burnett,et al. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. , 1998, American journal of physiology. Renal physiology.
[27] D. Webb,et al. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. , 1998, Circulation.
[28] M. Cicardi,et al. Plasma bradykinin in angio-oedema , 1998, The Lancet.
[29] X. Xu,et al. Neutral endopeptidase and angiotensin-converting enzyme inhibitors increase nitric oxide production in isolated canine coronary microvessels by a kinin-dependent mechanism. , 1998, Journal of cardiovascular pharmacology.
[30] L. Ghiadoni,et al. Effects of angiotensin converting enzyme inhibition on endothelium‐dependent vasodilatation in essential hypertensive patients , 1998, Journal of hypertension.
[31] N. Trippodo,et al. Effects of omapatrilat in low, normal, and high renin experimental hypertension. , 1998, American journal of hypertension.
[32] X. Xu,et al. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. , 1997, Circulation.
[33] G. B. John Mancini,et al. Angiotensin Converting Enzyme Inhibition, with Quinapril, Improves Endothelial Vasomotor Dysfunction in Patients with Coronary Artery Disease: the TREND Study (Trial on REversing ENdothelial Dysfunction) , 1996 .
[34] R. Nuesch,et al. Effects of cilazapril on vascular structure and function in essential hypertension. , 1996, Hypertension.
[35] T. Lüscher,et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. , 1996, Circulation.
[36] T. Lüscher,et al. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. , 1996, Hypertension.
[37] A. Mimran,et al. Contrasting effect of antihypertensive treatment on the renal response to L-arginine. , 1995, Hypertension.
[38] G. C. Butler,et al. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. , 1995, Hypertension.
[39] N. Trippodo,et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. , 1995, The Journal of pharmacology and experimental therapeutics.
[40] J. Cleland,et al. Renal response to candoxatrilat in patients with heart failure. , 1995, Journal of the American College of Cardiology.
[41] K. Margulies,et al. The role of neutral endopeptidase in dogs with evolving congestive heart failure. , 1995, Circulation.
[42] E. Schiffrin,et al. Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. , 1995, Hypertension.
[43] B. Abboa-Offei,et al. POTENTIATION OF NATRIURETIC PEPTIDES BY NEUTRAL ENDOPEPTIDASE INHIBITORS , 1995, Clinical and experimental pharmacology & physiology.
[44] M. Creager,et al. Effect of captopril and enalapril on endothelial function in hypertensive patients. , 1994, Hypertension.
[45] G. Wittert,et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II , 1993, Journal of hypertension.
[46] P. Vanhoutte,et al. Local production of kinins contributes to the endothelium dependent relaxations evoked by converting enzyme inhibitors in isolated arteries. , 1992, Agents and actions. Supplements.
[47] R. Busse,et al. Ramiprilat Enhances Endothelial Autacoid Formation by Inhibiting Breakdown of Endothelium‐Derived Bradykinin , 1991, Hypertension.
[48] S. Moncada,et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.
[49] G. Reeder,et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. , 1986, Science.
[50] J. Granger,et al. Effects of synthetic atrial natriuretic factor on renal function and renin release. , 1984, The American journal of physiology.